Long-term safety of etanercept and adalimumab compared to Methotrexate in patients with juvenile idiopathic arthritis (JIA)

Annals of the Rheumatic Diseases

Volumn 75, Issue 5, 2016, Pages 855-861

  Klotsche, Jens ^a   Niewerth, Martina ^a   Haas, Johannes Peter ^b   Huppertz, Hans Iko ^c   Zink, Angela ^a   Horneff, Gerd ^d   Minden, Kirsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Centre for Rheumatology in Children and Adolescents   (Germany)

^c Hess Children's Hospital   (Germany)

^d Asklepios Kinderklinik St Augustin GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHILD; CLINICAL HANDOVER; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; UVEITIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; GERMANY; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDY; REGISTER;

ADALIMUMAB; ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; CHILD; ETANERCEPT; FEMALE; GERMANY; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; METHOTREXATE; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84930403433     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-annrheumdis-2014-206747     Document Type: Article

References (53)

1. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
2. Flatø B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386-93.
3. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatol Oxf Engl 2002;41:1428-35.
4. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
5. Solari N, Viola S, Pistorio A, et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum 2008;59:1571-9.
6. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
7. Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatol Oxf Engl 2012;51:1407-15.
8. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
9. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.
10. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
11. Otten MH, Prince FHM, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA J Am Med Assoc 2011;306:2340-7.
12. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2014;73:1114-22.
13. Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatol Oxf Engl 2009;48:916-19.
14. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
15. Horneff G, Fitter S, Foeldvari I, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012;14:R230.
16. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
17. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
18. Klein A, Kaul I, Foeldvari I, et al. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res 2012;64:1349-56.
19. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
20. Foeldvari I, Ruperto N, Dressler F, et al. The German version of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S71-5.
21. Bruce B, Fries JF. The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78.
22. Swart JF, de Roock S, Wulffraat NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther 2013;15:213.
23. Dixon WG, Symmons DPM, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
24. Molenberghs G, Kenward MG. Missing data in clinical studies. Chichester; Hoboken, NJ: Wiley, 2007.
25. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiol Camb Mass 2000;11:550-60.
26. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
27. KPOH: Information portal on malignant diseases and diseases of the blood in children and young adults. http://www.kinderkrebsinfo.de/index-eng.html (accessed 26 Mar. 2014).
28. Prince FHM, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
29. Sevcic K, Orban I, Brodszky V, et al. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatol Oxf Engl 2011;50:1337-40.
30. Boerbooms AM, Kerstens PJ, van Loenhout JW, et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.
31. Schnabel A, Burchardi C, Gross WL. Major infection during methotrexate treatment for rheumatoid arthritis. Semin Arthritis Rheum 1996;25:357-9.
32. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24.
33. Ruperto N, Martini A. Juvenile idiopathic arthritis and malignancy. Rheumatol Oxf Engl 2014;53:968-74.
34. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64:1263-71.
35. Simard JF, Neovius M, Hagelberg S, et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010;62:3776-82.
36. Horneff G, Foeldvari I, Minden K, et al. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatol Oxf Engl 2011;50:230-6.
37. Beukelman T, Xie F, Baddley JW, et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum 2013;65:1384-9.
38. Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64:2773-80.
39. Horneff G, Becker I. Serious infections in juvenile idiopathic arthritis patients upon TNF inhibitors depend on disease activity. Ann Rheum Dis 2014;73(Suppl 2):114-5.
40. Ruemmele FM, Prieur A-M, Talbotec C, et al. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr 2004;39:203-6.
41. Van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441-6.
42. Sunseri W, Hyams JS, Lerer T, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1341-5.
43. Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatol Oxf Engl 2010;49:1694-8.
44. Kotaniemi K, Kautiainen H, Karma A, et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 2001;108:2071-5.
45. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24.
46. Sharma SM, Nestel AR, Lee RWJ, et al. Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 2009;17:403-14.
47. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatol Oxf Engl 2005;44:1008-11.
48. Smith JA, Thompson DJS, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23.
49. Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006;149:833-6.
50. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35:751-6.
51. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52.
52. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with Ocular Inflammatory Disorders. Ophthalmology 2014;121:785-96.e3.
53. Horneff G, Foeldvari I, Minden K, et al. Analysis of uveitis events in the Biologics in pediatric Rheumatolgy (BiKeR) registry. Ann Rheum Dis 2014;73(Suppl 2):133.